Document is current

Article History

Accepted: 14 April 2024

First Online: 29 April 2024

Declarations

:

: Shigeki Yamada has received honoraria from Nippon Shinyaku Co., Ltd, Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd. Tomohiro Mizuno is an editorial board member of <i>Clinical Drug Investigation</i>. Noriaki Matsumoto, Yosuke Ando, Koki Kato, Masanori Nakanishi, Tsuyoshi Nakai, Jeannie K. Lee, Yoshitaka Kameya, Wataru Nakamura, Kiyoshi Takahara, and Ryoichi Shiroki declare no conflicts of interest regarding the subject of this study.

: This study was approved by the Ethics Board of Fujita Health University Hospital (Ethics Committee approval number: HM23-027; date of approval 9 May 2023) and was conducted in accordance with the appropriate guidelines.

: Not applicable.

: An opt-out approach was used to obtain informed consent according to the guidelines of the Fujita Health University Hospital Ethics Board.

: Not applicable.

: NM contributed to the study conception and design and drafted the manuscript. NM, KK, MN, and TN analyzed and interpreted the data. YA, JKL, YK, WN, KT, RS, and SY contributed to the study design and reviewed the manuscript. TM contributed to the study conception and design, drafted the manuscript, and supervised the execution of the study.

: Data archiving is not mandated but data will be made available on reasonable request.

: This work was supported by the JSPS KAKENHI (grant number 21K06696) and the Research Center for Pathogenesis of Intractable Diseases, Research Institute of Meijo University, Japan.